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INTRODUCTION
Self-expanding Wingspan stents (Stryker Neurovascular) are 
approved by the Food and Drug Administration as an intracra-
nial stent for use in patients with intracranial atherosclerotic 
stenosis (ICAS) under the Humanitarian Device Exemption. 
However, Stenting and Aggressive Medical Management for 
Preventing Recurrent Stroke in Intracranial Stenosis (SAMM-
PRIS) trials and long-term outcome data have reported inferi-
or results for Wingspan stenting for ICAS compared to the best 
medical practice.1 Recent studies on Wingspan stenting for 
ICAS demonstrated low periprocedural complication rates 
and excellent safety profile when performed by experienced 
interventionalists with proper patient selection, following the 
recommended usage guidelines.1,2
In-stent stenosis is a potential concern in stent-assisted coil-
ing (SAC) for intracranial aneurysms. Intracranial stents may 
exhibit flow-remodeling effects through neoendothelialization, 
which could result in in-stent stenosis.3,4 It can be diagnosed 
with computed tomography angiography, magnetic resonance 
angiography (MRA), or digital subtraction angiography (DSA). 
Most patients with in-stent stenosis are asymptomatic.3-5 How-
ever, some symptomatic cases require additional treatment 
with anti-platelet agents, angioplasty, and bypass surgery.4,6 
There is no single case report or analysis of the long-term follow-
up results of in-stent stenosis treated by the Wingspan stent. 
Moreover, there is no existing guideline for the treatment of 
symptomatic in-stent stenosis cases.
Herein, we report the long-term follow-up result of a patient 
who was treated with the Wingspan stent for symptomatic in-
stent stenosis of a closed-cell stent, which was implanted during 
SAC of a ruptured intracranial aneurysm. This use circumvent-
ed its on-label indication of symptomatic iatrogenic intracrani-
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A middle-aged person presented to our institution with tran-
sient right-side weakness. The patient was a non-smoker and 
did not have any past medical history, such as hypertension, 
diabetes, or dyslipidemia. The patient had experienced sub-
arachnoid hemorrhage caused by a ruptured aneurysm on 
the left internal carotid artery (ICA) a year earlier, which was 
treated with SAC using a self-expanding closed-cell Enterprise 
stent (Codman Neurovascular) at another hospital. Diffusion-
weighted imaging (DWI) at admission showed no acute in-
farction; DSA showed severe stenosis (90%) of the left M1 distal 
to the distal end of the Enterprise stent (Fig. 1). The patient was 
on a regimen of anti-platelet monotherapy-aspirin (100 mg/
day). Clopidogrel (75 mg/day) was initiated additionally.
However, the patient experienced repeated right-side numb-
ness and mild weakness after 8 months on dual anti-platelet 
therapy. The symptoms were transient but occurred twice a 
week. DWI showed small lesions with high signal intensity on 
the left temporal lobe (Fig. 2A). A follow-up DSA showed se-
vere in-stent stenosis of the left M1 when compared to previ-
ous DSA results (Fig. 2B). Despite dual anti-platelet therapy, 
the patient’s symptoms persisted, which warranted Wingspan 
stenting. Under general anesthesia, a 6-Fr guiding catheter was 
placed in the left ICA. A Gateway balloon (2.25×9 mm, Stryker 
Neurovascular) was mounted up to the left M1 using a 300-cm 
exchange microwire. After pre-ballooning with the Gateway 
balloon, a Wingspan stent (4.5×15 mm) was placed at the lesion 
(Fig. 2C). DSA performed immediately after stenting showed 
good expansion of the in-stent stenosis and sufficient distal 
middle cerebral artery flow (Fig. 2D). There was no procedure-
related complication, and the patient was discharged without 
any neurological deficit.
Follow-up DSA performed 1 year after the Wingspan stent-
ing showed good patency of the middle cerebral artery flow 
without evidence of restenosis (Fig. 2E). Clopidogrel was dis-
continued, and only aspirin monotherapy was maintained. Af-
ter 2 more years of follow-up, MRA showed sufficient middle 
cerebral artery flow, although the stenting segment could not 
be visualized clearly.
Written informed consent was obtained from the patient.
A B
Fig. 1. Digital subtraction angiography. (A) It showed severe stenosis (90%) of the left M1 distal to the distal end of the Enterprise stent. (B) Dyna-comput-
ed tomography showed a precise relationship between the distal end of the stent and M1 stenosis. White arrow indicates the left M1 stenosis; white ar-
row head indicates the distal markers of the Enterprise stent. 
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DISCUSSION
In the present case, we reported a long-term follow-up result 
of Wingspan stenting for symptomatic severe in-stent stenosis 
of a closed-cell stent used for SAC, and Wingspan stenting 
showed good patency without evidence of restenosis. Since 
the patient did not have any risk factor for intracranial arterial 
stenosis, the cause of in-stent stenosis in the present case might 
be endothelial stimulation by the distal markers of the Enter-
prise in the very proximal part of M1 segment.
The incidence of in-stent stenosis is known to be approxi-
mately 2.3–7.8%, and it remains a valid concern in the case of 
SAC.3-6 To prevent this issue, dual anti-platelet therapy is used 
initially, and is subsequently changed to aspirin monotherapy, 
which is maintained thereafter. If patients experienced symp-
toms and signs due to in-stent stenosis, there might be some 
treatment options, such as bypass surgery, balloon angioplasty, 
or intracranial stenting. However, there is no specific guide-
line available for treating cases of symptomatic severe in-stent 
stenosis. Therefore, sharing and reporting the treatment tech-
nique and result of prospective cases will be helpful to identify 
the appropriate treatment options in the future. In this regard, 
therefore, we believe the present case offers significant value.
There have been 37 reports mentioning in-stent stenosis in 
cases of SAC. Most were asymptomatic cases. Even in symp-
tomatic in-stent stenosis, there were few reports on the treat-
ment of in-stent stenosis. Since the first report in 2006, there 
have been 6 reported cases that were treated for symptomatic 
A
B C D E
Fig. 2. Images after repeated symptoms. (A) Diffusion-weighted image shows small lesions with high signal intensity on the left temporal lobe. (B) Fol-
low-up digital subtraction angiography (DSA) shows severe in-stent stenosis of the left M1. (C) After pre-ballooning using a Gateway balloon, a Wing-
span stent (4.5×15 mm) was placed at the lesion. (D) DSA performed immediately after stenting showed good expansion of the in-stent stenosis and 
sufficient distal middle cerebral artery flow. (E) Follow-up DSA 1 year after Wingspan stenting showed good patency of the middle cerebral artery flow, 
without evidence of restenosis. White circle indicates multiple small high signal lesions; white arrow indicates the left M1 stenosis; black arrowheads 
indicate the proximal and distal markers of the Wingspan stent.
Table 1. List of the 6 Cases Treated for Symptomatic In-Stent Stenosis in Stents Used for Coiling of Intracranial Aneurysms








Fiorella et al. 20064
Right ICA terminus Cerebral infarction Neuroform   3 Not mentioned PTA & direct bypass
Right ICA posterior wall Transient ischemic attack Neuroform   3 Not mentioned PTA
Gao et al. 20108 Right PcoA Cerebral infarction Neuroform 13 Not mentioned PTA












AcoA, anterior communicating artery; ICA, internal carotid artery; MCA, middle cerebral artery; PcoA, posterior communicating artery; PTA, percutaneous trans-
luminal balloon angioplasty.
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in-stent stenosis in stents used for coiling of intracranial aneu-
rysms (Table 1).4,7-9 No report has mentioned long-term follow-
up result of in-stent stenosis treatment, except for the present 
case. Moreover, only in the present case, symptomatic in-stent 
stenosis by a closed-cell stent, the Enterprise stent, was treated. 
Furthermore, the treatment of in-stent stenosis using Wing-
span stenting was reported for the first time in this report. How-
ever, further study with a longer term follow-up (of more than 3 
years) DSA is needed, due to the possibility of asymptomatic 
restenosis of the Wingspan stent.
In the WEAVE trial,2 a low periprocedural event rate of in-
tracranial stenting was observed compared to the SAMMPRIS 
trial (2.6% vs. 14.7%). The trial showed the importance of ex-
perienced interventionalists and proper patient selection fol-
lowing the on-label usage guidelines. Compared with previ-
ous studies, the patients enrolled in the WEAVE trial had more 
severe stenosis (70–99%) and more than 2 qualifying strokes, 
were refractory to medical therapy, and were stented with Wing-
span ≥8 days after the last stroke (median time to stent, 22 days). 
Despite its off-label use in the present case, the treatment of 
symptomatic in-stent stenosis with a Wingspan stent showed 
good results in long-term follow-up. Therefore, we believe 
that the use of Wingspan stent could be a good treatment op-
tion for patients with symptomatic in-stent stenosis. The off-
label use of Wingspan stent has not been studied yet; howev-
er, a detailed report of ongoing treatment results is warranted 
for objective assessment.
In conclusion, Wingspan stenting might be a feasible option 
in patients with symptomatic in-stent stenosis after SAC, de-
spite dual anti-platelet therapy. Moreover, a good long-term 
patency can be expected from this treatment approach.
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